1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Adocia S.A.

Adocia S.A.

ADOCY
Adocia S.A.US flagOther OTC
11.80
USD
- -
- -
170.44MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
Revenue per Share
0.67
0.9
0.11
5.52
3.28
2.84
6.85
0.31
0.12
0.2
1.43
0.15
0.63
Basic EPS, GAAP
-1
-0.69
-3.33
1.88
-1.15
-1.25
1.1
-2.68
-3.34
-3.22
-0.86
-1.5
-0.63
Free Cash Flow per Basic Share
0.03
-1.81
4.85
-1.12
-3.1
-3.53
0.8
-1.68
-3.16
-2.78
-1.89
-0.36
-1.07
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.9
-0.59
-3.23
1.98
-1.05
-1.15
1.2
-2.58
-3.24
-3.12
-0.75
-1.4
-0.52
Tangible Book Value per Share
3.85
3.08
0.4
7.03
6.25
5.36
6.61
4.03
0.9
-1.96
-1.62
-0.49
-0.21
Basic Weighted Avg Shares
6
6
6
7
7
7
7
7
7
7
8
14
15
Sales/Revenue/Turnover
4
6
1
37
22
19
47
2
1
1
11
2
9
Operating Margin (%)
-151.9
-76.95
-2,437.5
27.35
-35.58
-42.01
20.49
-1,027.53
-2,514.74
-1,341.07
-14.82
-662.51
-79.41
Depreciation Expense
- -
- -
- -
1
1
1
1
1
1
1
1
- -
- -
Net Income, GAAP
-6
-4
-21
13
-8
-9
8
-19
-23
-23
-7
-21
-9
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
35.24
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-150.03
-76.81
-2,942.47
33.98
-35.09
-43.92
16.07
-868.08
-2,773.37
-1,575.76
-60.29
-984.28
-100
Working Capital
24
20
31
66
42
36
46
41
26
-2
1
- -
2
LT Debt
2
2
1
1
6
6
5
19
25
18
18
11
9
Total Equity
23
19
3
47
43
37
46
28
6
-14
-13
-7
-3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
12.82
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
101.89
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
123.73%
-100.73%
-55.32%
Free Cash Flow
-16.28%
39.81%
210.24%
Net Income, GAAP
-74.45%
20.79%
-55.95%
Sales/Revenue/Turnover
609.81%
191.2%
333.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
11
2023
- -
- -
- -
- -
2
2024
- -
- -
- -
- -
9

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.86
2023
- -
- -
- -
- -
-1.5
2024
- -
- -
- -
- -
-0.63

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Olivier Soula
Full Time Employees
78
Sector
Healthcare
Industry
Biotechnology
Address
115 Avenue Lacassagne Lyon France 69003
IPO Date
Aug 18, 2014
Website
adocia.com
Similar Companies
Syngene International Limited (SYNGENE.NS)
Biotest AG (BIO.DE)
Synbio Tech Inc. (1295.TWO)
JW (Cayman) Therapeutics Co. Ltd (2126.HK)
Bionomics Limited (BNO.AX)
Cyteir Therapeutics, Inc. (CYT)
Business
Adocia SA (ADOCY) is a French clinical-stage biotechnology company that develops innovative formulations of approved therapeutic proteins and peptides, as well as cell therapy approaches, primarily for the treatment of diabetes and obesity. Founded in 2005 and headquartered in Lyon, France, the company operates through four proprietary technology platforms—BioChaperone®, AdoShell®, AdOral®, and AdoGel®—targeting type 1 and type 2 diabetes, obesity, and related metabolic diseases; its diversified pipeline includes BioChaperone Lispro, an ultra-rapid prandial insulin formulation licensed to Tonghua Dongbao Pharmaceutical Co., Ltd. for China and select Asian territories, which completed Phase 3 trials with positive topline results in type 1 and type 2 diabetes patients in 2025; BioChaperone Combo, a fixed combination of insulin glargine and lispro for improved glycemic control in type 2 diabetes; M1Pram and BioChaperone LisPram, co-formulations of insulin analogs with pramlintide (amylin analog) under exclusive option rights with Sanofi for obesity management in insulin-dependent patients; AdoShell Islets, an immunoprotective hydrogel implant for retrievable islet cell therapy in type 1 diabetes; AdOral Sema, an oral semaglutide GLP-1 receptor agonist; AdoGel Sema, a long-acting injectable hydrogel for semaglutide delivery; and BioChaperone GLP-1 Amylin, a combination for metabolic control. Adocia focuses on licensing its products and platforms to pharmaceutical partners after human proof-of-concept, with operations centered in Europe and strategic alliances extending to Asia and potential global expansion. Recent developments include a €10 million fundraising in December 2025 from CVI Investments, Inc., extending cash runway into early 2027 and supporting industrialization of BioChaperone technology and the new AdoXLong long-acting peptide platform for which a patent was filed in November 2025; a €9.7 million private placement in February 2025; positive Phase 3 data announcements with Tonghua Dongbao in mid-2025 for BioChaperone Lispro; ongoing partnership discussions with Sanofi for M1Pram; and presentations on AdoShell scalability at scientific conferences in 2025.